Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.
Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.
Explore the multifaceted impact of desmoid tumors on patients’ physical, functional, and psychosocial well-being as experts emphasize effective symptom management and quality-of-life enhancements.
Explore effective approaches in handling fatigue, insomnia, and financial difficulties of patients with desmoid tumors as experts highlight psychosocial support and treatment considerations for quality care.
Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.